Gerson Suarez-Cedeno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gerson Suarez-Cedeno has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Velez-Pardo
Neuroscience Research Group, Institute of Medical Research, Faculty of Medicine, University of Antioquia, University Research Headquarters, Calle 62#52-59, Building 1, Laboratory 411/412, Medellin 050010, Colombia
1 shared publication Jessika Suescun
Department of Neurology, The University of Texas McGovern Medical School at Houston, Houston, TX, USA
1 shared publication- Margherita Milone
Department of Neurology, Mayo Clinic, Rochester, MN
1 shared publication - Marlene Jimenez-Del-Rio
Neuroscience Research Group, Institute of Medical Research, Faculty of Medicine, University of Antioquia, University Research Headquarters, Calle 62#52-59, Building 1, Laboratory 411/412, Medellin 050010, Colombia
1 shared publication - Mya Caryn Schiess
Department of Neurology, University of Texas Health Sciences Center at Houston, Houston, TX 77030, USA
1 shared publication Thomas Winder
Prevention Genetics; Marshfield; Wisconsin USA
1 shared publication
Latest Publications
- Open Access
- 16 August 2017
- Published by Wiley in Parkinson's Disease
- Vol. 2017, 1-9
Earlier Intervention with Deep Brain Stimulation for Parkinson’s Disease
Neuromodulation of subcortical areas of the brain as therapy to reduce Parkinsonian motor symptoms was developed in the mid-twentieth century and went through many technical and scientific advances that established specific targets and stimulation parameters. Deep Brain Stimulation (DBS) was approved by the FDA in 2002 as neuromodulation therapy for advanced Parkinson’s disease, prompting several randomized controlled trials that confirmed its safety and effectiveness. The implantation of tens of thousands of patients in North America and Europe ignited research into its potential role in early disease stages and the therapeutic benefit of DBS compared to best medical therapy. In 2013 the EARLY-STIM trial provided Class I evidence for the use of DBS earlier in Parkinson’s disease. This finding led to the most recent FDA approval in patients with at least 4 years of disease duration and 4 months of motor complications as an adjunct therapy for patients not adequately controlled with medications. This following review highlights the historical development and advances made overtime in DBS implantation, the current application, and the challenges that come with it.
- 16 August 2017
- Published by Wiley in Parkinson's Disease
- Vol. 2017, 1-9
Open AccessEarlier Intervention with Deep Brain Stimulation for Parkinson’s Disease
Neuromodulation of subcortical areas of the brain as therapy to reduce Parkinsonian motor symptoms was developed in the mid-twentieth century and went through many technical and scientific advances that established specific targets and stimulation parameters. Deep Brain Stimulation (DBS) was approved by the FDA in 2002 as neuromodulation therapy for advanced Parkinson’s disease, prompting several randomized controlled trials that confirmed its safety and effectiveness. The implantation of tens of thousands of patients in North America and Europe ignited research into its potential role in early disease stages and the therapeutic benefit of DBS compared to best medical therapy. In 2013 the EARLY-STIM trial provided Class I evidence for the use of DBS earlier in Parkinson’s disease. This finding led to the most recent FDA approval in patients with at least 4 years of disease duration and 4 months of motor complications as an adjunct therapy for patients not adequately controlled with medications. This following review highlights the historical development and advances made overtime in DBS implantation, the current application, and the challenges that come with it.
- 24 February 2014
- Published by Wiley in Muscle & Nerve
- Vol. 49 (4) , 607-610
DNAJB6 myopathy: A vacuolar myopathy with childhood onset
Introduction: DNAJB6 mutations cause an autosomal dominant myopathy that can manifest as limb‐girdle muscular dystrophy (LGMD1D/1E) or distal‐predominant myopathy. In the majority of patients this myopathy manifests in adulthood and shows vacuolar changes on muscle biopsy. Methods: Clinical, electrophysiological, pathological, and molecular findings are reported. Results: We report a 56‐year‐old woman, who, like 3 other family members, became symptomatic in childhood with slowly progressive limb‐girdle muscle weakness, normal serum creatine kinase (CK) values, and myopathic electromyographic findings. Muscle biopsy showed vacuolar changes and congophilic inclusions, and molecular analysis revealed a pathogenic mutation in the DNAJB6 gene. Differences and similarities with previously described cases are assessed. Conclusions: Childhood‐onset of DNAJB6 myopathy is more frequent than previously believed; congophilic inclusions may be present in the muscle of these patients. Muscle Nerve 49:607–610, 2014
- 24 February 2014
- Published by Wiley in Muscle & Nerve
- Vol. 49 (4) , 607-610
DNAJB6 myopathy: A vacuolar myopathy with childhood onset
Introduction: DNAJB6 mutations cause an autosomal dominant myopathy that can manifest as limb‐girdle muscular dystrophy (LGMD1D/1E) or distal‐predominant myopathy. In the majority of patients this myopathy manifests in adulthood and shows vacuolar changes on muscle biopsy. Methods: Clinical, electrophysiological, pathological, and molecular findings are reported. Results: We report a 56‐year‐old woman, who, like 3 other family members, became symptomatic in childhood with slowly progressive limb‐girdle muscle weakness, normal serum creatine kinase (CK) values, and myopathic electromyographic findings. Muscle biopsy showed vacuolar changes and congophilic inclusions, and molecular analysis revealed a pathogenic mutation in the DNAJB6 gene. Differences and similarities with previously described cases are assessed. Conclusions: Childhood‐onset of DNAJB6 myopathy is more frequent than previously believed; congophilic inclusions may be present in the muscle of these patients. Muscle Nerve 49:607–610, 2014
- Open Access
- 12 March 2010
- Published by Wiley in Biochemistry and Molecular Biology Education
- Vol. 38 (2) , 104-109
Using paraquat to generate anion free radicals and hydrogen peroxide in in vitro: Antioxidant effect of vitamin E
The theoretical basis of reactive oxygen species and their impact on health issues are relatively easy to understand by biomedical students. The detection of reactive oxygen species requires expensive equipment, the procedures are time consuming and costly, and the results are hard to interpret. Moreover, cause‐and‐effect relationships in the living system are not so evident. In this report, we adapted a two‐step procedure to detect anion superoxide radicals and hydrogen peroxide generation in lymphocytes exposed to paraquat by using nitroblue tetrazolium salt and dihydrorhodamine, respectively. Also, a two‐step assay was performed to evaluate lymphocyte viability and nuclei morphologic changes on paraquat exposure for 1 and 24 hours incubation time by using trypan blue exclusion assay and acridine orange/ethidium bromide staining technique, respectively. Vitamin E was used as antioxidant to inhibit the deleterious effects of paraquat on cells. Students learned how to (i) design and perform experiments in the laboratory, (ii) read critical scientific literature, and (iii) discuss and contrast relevant information about reactive oxygen species as causative agents of cell death phenomenon.
- 12 March 2010
- Published by Wiley in Biochemistry and Molecular Biology Education
- Vol. 38 (2) , 104-109
Open AccessUsing paraquat to generate anion free radicals and hydrogen peroxide in in vitro: Antioxidant effect of vitamin E
The theoretical basis of reactive oxygen species and their impact on health issues are relatively easy to understand by biomedical students. The detection of reactive oxygen species requires expensive equipment, the procedures are time consuming and costly, and the results are hard to interpret. Moreover, cause‐and‐effect relationships in the living system are not so evident. In this report, we adapted a two‐step procedure to detect anion superoxide radicals and hydrogen peroxide generation in lymphocytes exposed to paraquat by using nitroblue tetrazolium salt and dihydrorhodamine, respectively. Also, a two‐step assay was performed to evaluate lymphocyte viability and nuclei morphologic changes on paraquat exposure for 1 and 24 hours incubation time by using trypan blue exclusion assay and acridine orange/ethidium bromide staining technique, respectively. Vitamin E was used as antioxidant to inhibit the deleterious effects of paraquat on cells. Students learned how to (i) design and perform experiments in the laboratory, (ii) read critical scientific literature, and (iii) discuss and contrast relevant information about reactive oxygen species as causative agents of cell death phenomenon.